Antagonists of IL-6 to raise albumin and/or lower CRP
AssigneeAlderbio Holdings LLC
InventorJeffrey T. L. Smith
Life of this patent
Estimating the term…
Abstract
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
Claims14
A method of reducing serum C-reactive protein (“CRP”) level in a patient with an inflammatory condition wherein interleukin-6 (“IL-6”) is elevated by administering an effective amount of an anti-IL-6 antibody comprising the variable heavy and light chain polypeptides of SEQ ID NO:657 and SEQ ID NO:709 respectively and the constant regions of SEQ ID NO:588 and 586 and monitoring the patient to assess the reduction in the patient's serum CRP level.
A method of increasing serum albumin level in a patient with an inflammatory condition wherein interleukin-6 (“IL-6”) is elevated by administering an effective amount of an anti-IL-6 antibody comprising the variable heavy and light chain polypeptides of SEQ ID NO:657 and SEQ ID NO:709 respectively and the constant regions of SEQ ID NO:588 and 586, and monitoring the patient to assess the increase in the patient's serum albumin level.
A method of reducing a patient's serum CRP level and increasing the patient's serum albumin level in a patient with an inflammatory condition wherein interleukin-6 (“IL-6”) is elevated by administering an effective amount of an anti-IL-6 antibody comprising the variable heavy and light chain polypeptides of SEQ ID NO:657 and SEQ ID NO:709 respectively and the constant regions of SEQ ID NO:588 and 586, and monitoring the patient to assess the reduction in the patient's serum CRP level and the increase in the patient's serum albumin level.
Dependencies are inferred from the claim text.